Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Systems pharmacology-based integration of human and mouse data for drug repurposing to treat thoracic aneurysms.

Hansen J, Galatioto J, Caescu CI, Arnaud P, Calizo RC, Spronck B, Murtada SI, Borkar R, Weinberg A, Azeloglu EU, Bintanel-Morcillo M, Gallo JM, Humphrey JD, Jondeau G, Boileau C, Ramirez F, Iyengar R.

JCI Insight. 2019 Jun 6;4(11). pii: 127652. doi: 10.1172/jci.insight.127652. eCollection 2019 Jun 6.

2.

A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-α mediates C9orf72-related neurodegeneration.

Solomon DA, Stepto A, Au WH, Adachi Y, Diaper DC, Hall R, Rekhi A, Boudi A, Tziortzouda P, Lee YB, Smith B, Bridi JC, Spinelli G, Dearlove J, Humphrey DM, Gallo JM, Troakes C, Fanto M, Soller M, Rogelj B, Parsons RB, Shaw CE, Hortobágyi T, Hirth F.

Brain. 2018 Oct 1;141(10):2908-2924. doi: 10.1093/brain/awy241.

3.

Modulation of Cell State to Improve Drug Therapy.

Gallo JM.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):539-542. doi: 10.1002/psp4.12317. Epub 2018 Aug 8. No abstract available.

4.

Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy.

Espíndola SL, Damianich A, Alvarez RJ, Sartor M, Belforte JE, Ferrario JE, Gallo JM, Avale ME.

Cell Rep. 2018 Apr 17;23(3):709-715. doi: 10.1016/j.celrep.2018.03.079.

5.

C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity.

Lee YB, Baskaran P, Gomez-Deza J, Chen HJ, Nishimura AL, Smith BN, Troakes C, Adachi Y, Stepto A, Petrucelli L, Gallo JM, Hirth F, Rogelj B, Guthrie S, Shaw CE.

Hum Mol Genet. 2017 Dec 15;26(24):4765-4777. doi: 10.1093/hmg/ddx350.

6.

RNA Misprocessing in C9orf72-Linked Neurodegeneration.

Barker HV, Niblock M, Lee YB, Shaw CE, Gallo JM.

Front Cell Neurosci. 2017 Jul 11;11:195. doi: 10.3389/fncel.2017.00195. eCollection 2017. Review.

7.

CNS Anticancer Drug Discovery and Development: 2016 conference insights.

Levin VA, Abrey LE, Heffron TP, Tonge PJ, Dar AC, Weiss WA, Gallo JM.

CNS Oncol. 2017 Jul 18. doi: 10.2217/cns-2017-0014. [Epub ahead of print]

8.

Tau Isoforms Imbalance Impairs the Axonal Transport of the Amyloid Precursor Protein in Human Neurons.

Lacovich V, Espindola SL, Alloatti M, Pozo Devoto V, Cromberg LE, Čarná ME, Forte G, Gallo JM, Bruno L, Stokin GB, Avale ME, Falzone TL.

J Neurosci. 2017 Jan 4;37(1):58-69. doi: 10.1523/JNEUROSCI.2305-16.2016.

9.
10.

Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug.

Wang T, Pickard AJ, Gallo JM.

Anticancer Res. 2016 Jul;36(7):3289-99.

11.

Tau mis-splicing in the pathogenesis of neurodegenerative disorders.

Park SA, Ahn SI, Gallo JM.

BMB Rep. 2016 Aug;49(8):405-13. Review.

12.

Identification and Correction of Mechanisms Underlying Inherited Blindness in Human iPSC-Derived Optic Cups.

Parfitt DA, Lane A, Ramsden CM, Carr AJ, Munro PM, Jovanovic K, Schwarz N, Kanuga N, Muthiah MN, Hull S, Gallo JM, da Cruz L, Moore AT, Hardcastle AJ, Coffey PJ, Cheetham ME.

Cell Stem Cell. 2016 Jun 2;18(6):769-81. doi: 10.1016/j.stem.2016.03.021. Epub 2016 Apr 14.

13.

Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD.

Niblock M, Smith BN, Lee YB, Sardone V, Topp S, Troakes C, Al-Sarraj S, Leblond CS, Dion PA, Rouleau GA, Shaw CE, Gallo JM.

Acta Neuropathol Commun. 2016 Feb 25;4:18. doi: 10.1186/s40478-016-0289-4.

14.

Lack of association between TDP-43 pathology and tau mis-splicing in Alzheimer's disease.

Niblock M, Hortobágyi T, Troakes C, Al-Sarraj S, Spickett C, Jones R, Shaw CE, Gallo JM.

Neurobiol Aging. 2016 Jan;37:45-46. doi: 10.1016/j.neurobiolaging.2015.09.022. Epub 2015 Oct 9.

15.

CNS Anticancer Drug Discovery and Development Conference White Paper.

Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC.

Neuro Oncol. 2015 Nov;17 Suppl 6:vi1-26. doi: 10.1093/neuonc/nov169.

16.

Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration.

Gomez-Deza J, Lee YB, Troakes C, Nolan M, Al-Sarraj S, Gallo JM, Shaw CE.

Acta Neuropathol Commun. 2015 Jun 25;3:38. doi: 10.1186/s40478-015-0218-y.

17.

Network pharmacodynamic models for customized cancer therapy.

Gallo JM, Birtwistle MR.

Wiley Interdiscip Rev Syst Biol Med. 2015 Jul-Aug;7(4):243-51. doi: 10.1002/wsbm.1300. Epub 2015 Apr 24.

18.

Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.

Liu Z, Yao Y, Kogiso M, Zheng B, Deng L, Qiu JJ, Dong S, Lv H, Gallo JM, Li XN, Song Y.

J Med Chem. 2014 Oct 23;57(20):8307-18. doi: 10.1021/jm500660f. Epub 2014 Oct 1.

19.

Solvent effects in acid-catalyzed biomass conversion reactions.

Mellmer MA, Sener C, Gallo JM, Luterbacher JS, Alonso DM, Dumesic JA.

Angew Chem Int Ed Engl. 2014 Oct 27;53(44):11872-5. doi: 10.1002/anie.201408359. Epub 2014 Sep 11.

PMID:
25214063
20.

Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease.

Sassi C, Guerreiro R, Gibbs R, Ding J, Lupton MK, Troakes C, Al-Sarraj S, Niblock M, Gallo JM, Adnan J, Killick R, Brown KS, Medway C, Lord J, Turton J, Bras J; Alzheimer's Research UK Consortium, Morgan K, Powell JF, Singleton A, Hardy J.

Neurobiol Aging. 2014 Dec;35(12):2881.e1-2881.e6. doi: 10.1016/j.neurobiolaging.2014.06.002. Epub 2014 Jun 16.

21.

Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors.

Ballesta A, Zhou Q, Zhang X, Lv H, Gallo JM.

CPT Pharmacometrics Syst Pharmacol. 2014 Apr 30;3:e112. doi: 10.1038/psp.2014.9.

22.

Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells.

Nishimura AL, Shum C, Scotter EL, Abdelgany A, Sardone V, Wright J, Lee YB, Chen HJ, Bilican B, Carrasco M, Maniatis T, Chandran S, Rogelj B, Gallo JM, Shaw CE.

PLoS One. 2014 Mar 20;9(3):e91269. doi: 10.1371/journal.pone.0091269. eCollection 2014.

23.

Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.

Zhang X, Lv H, Zhou Q, Elkholi R, Chipuk JE, Reddy MV, Reddy EP, Gallo JM.

Mol Cancer Ther. 2014 May;13(5):1105-16. doi: 10.1158/1535-7163.MCT-13-0847. Epub 2014 Feb 25.

24.

The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.

Sane R, Wu SP, Zhang R, Gallo JM.

Drug Metab Dispos. 2014 Apr;42(4):537-40. doi: 10.1124/dmd.113.055228. Epub 2014 Jan 24.

25.

Mechanistic vs. Empirical network models of drug action.

Birtwistle MR, Mager DE, Gallo JM.

CPT Pharmacometrics Syst Pharmacol. 2013 Sep 6;2:e72. doi: 10.1038/psp.2013.51.

26.

A General Network Pharmacodynamic Model-Based Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway.

Zhang XY, Birtwistle MR, Gallo JM.

CPT Pharmacometrics Syst Pharmacol. 2014 Jan 15;3:e92. doi: 10.1038/psp.2013.65.

27.

Tau mRNA is present in axonal RNA granules and is associated with elongation factor 1A.

Malmqvist T, Anthony K, Gallo JM.

Brain Res. 2014 Oct 10;1584:22-7. doi: 10.1016/j.brainres.2013.12.033. Epub 2014 Jan 2.

PMID:
24389033
28.

Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia.

Stepto A, Gallo JM, Shaw CE, Hirth F.

Acta Neuropathol. 2014 Mar;127(3):377-89. doi: 10.1007/s00401-013-1235-1. Epub 2013 Dec 24. Review.

PMID:
24366528
29.

Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic.

Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, Troakes C, Nishimura AL, Scotter EL, Vance C, Adachi Y, Sardone V, Miller JW, Smith BN, Gallo JM, Ule J, Hirth F, Rogelj B, Houart C, Shaw CE.

Cell Rep. 2013 Dec 12;5(5):1178-86. doi: 10.1016/j.celrep.2013.10.049. Epub 2013 Nov 27.

30.

A tailored microenvironment for catalytic biomass conversion in inorganic-organic nanoreactors.

Alamillo R, Crisci AJ, Gallo JM, Scott SL, Dumesic JA.

Angew Chem Int Ed Engl. 2013 Sep 23;52(39):10349-51. doi: 10.1002/anie.201304693. Epub 2013 Aug 1. No abstract available.

PMID:
23913846
31.

Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.

Sharma J, Lv H, Gallo JM.

Cancer Res. 2013 Aug 15;73(16):5242-52. doi: 10.1158/0008-5472.CAN-13-0690. Epub 2013 Jun 24.

32.

Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.

Reddy MV, Mallireddigari MR, Pallela VR, Cosenza SC, Billa VK, Akula B, Subbaiah DR, Bharathi EV, Padgaonkar A, Lv H, Gallo JM, Reddy EP.

J Med Chem. 2013 Jul 11;56(13):5562-86. doi: 10.1021/jm400575x. Epub 2013 Jun 25.

33.

Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models.

Tiwari AK, Zhang R, Gallo JM.

Mol Cancer Ther. 2013 Jul;12(7):1343-55. doi: 10.1158/1535-7163.MCT-13-0100. Epub 2013 May 1.

34.

Trans-splicing correction of tau isoform imbalance in a mouse model of tau mis-splicing.

Avale ME, Rodríguez-Martín T, Gallo JM.

Hum Mol Genet. 2013 Jul 1;22(13):2603-11. doi: 10.1093/hmg/ddt108. Epub 2013 Mar 3.

35.

Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition.

Gallo JM.

Clin Pharmacol Ther. 2013 Mar;93(3):236-8. doi: 10.1038/clpt.2012.244. Epub 2012 Dec 18. No abstract available.

PMID:
23340476
36.

Conversion of hemicellulose into furfural using solid acid catalysts in γ-valerolactone.

Gürbüz EI, Gallo JM, Alonso DM, Wettstein SG, Lim WY, Dumesic JA.

Angew Chem Int Ed Engl. 2013 Jan 21;52(4):1270-4. doi: 10.1002/anie.201207334. Epub 2012 Dec 4. No abstract available.

PMID:
23212945
37.

Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.

Lv H, Zhang X, Sharma J, Reddy MV, Reddy EP, Gallo JM.

AAPS J. 2013 Jan;15(1):250-7. doi: 10.1208/s12248-012-9428-4. Epub 2012 Nov 22.

38.

Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.

Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Patel A, Talele TT, Fu L, Kaddoumi A, Gallo JM, Chen ZS.

Cancer Lett. 2013 Jan 28;328(2):307-17. doi: 10.1016/j.canlet.2012.10.001. Epub 2012 Oct 9.

39.

Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM.

J Pharmacol Exp Ther. 2012 Nov;343(2):509-19. doi: 10.1124/jpet.112.196097. Epub 2012 Aug 6.

40.

Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.

Sharma J, Lv H, Gallo JM.

J Pharm Sci. 2012 Nov;101(11):4100-6. doi: 10.1002/jps.23283. Epub 2012 Aug 1.

PMID:
22865095
41.

Tau alternative splicing in familial and sporadic tauopathies.

Niblock M, Gallo JM.

Biochem Soc Trans. 2012 Aug;40(4):677-80. doi: 10.1042/BST20120091. Review.

PMID:
22817715
42.

Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy.

Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, Reddy EP, Gallo JM.

Pharm Res. 2012 Sep;29(9):2499-511. doi: 10.1007/s11095-012-0780-y. Epub 2012 Jun 8.

PMID:
22678771
43.

Merging systems biology with pharmacodynamics.

Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM.

Sci Transl Med. 2012 Mar 21;4(126):126ps7. doi: 10.1126/scitranslmed.3003563. Review.

44.

Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.

Lv H, Wang F, Reddy MV, Zhou Q, Zhang X, Reddy EP, Gallo JM.

Invest New Drugs. 2012 Dec;30(6):2263-73. doi: 10.1007/s10637-012-9806-x. Epub 2012 Mar 1.

45.

Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.

Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM.

J Pharm Biomed Anal. 2011 Dec 15;56(5):1117-20. doi: 10.1016/j.jpba.2011.08.003. Epub 2011 Aug 9.

46.

Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.

Wang Z, Zhou Q, Kruh GD, Gallo JM.

Drug Metab Dispos. 2011 Nov;39(11):2155-61. doi: 10.1124/dmd.111.041228. Epub 2011 Aug 12.

47.

Absence of disturbed axonal transport in spinal and bulbar muscular atrophy.

Malik B, Nirmalananthan N, Bilsland LG, La Spada AR, Hanna MG, Schiavo G, Gallo JM, Greensmith L.

Hum Mol Genet. 2011 May 1;20(9):1776-86. doi: 10.1093/hmg/ddr061. Epub 2011 Feb 11.

48.

The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.

Zhou Q, Gallo JM.

AAPS J. 2011 Mar;13(1):111-20. doi: 10.1208/s12248-011-9253-1. Epub 2011 Jan 19. Review.

49.

Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.

Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G.

Mol Pharm. 2010 Dec 6;7(6):2255-69. doi: 10.1021/mp100235w. Epub 2010 Nov 8.

PMID:
20958082
50.

Pharmacokinetic/ pharmacodynamic-driven drug development.

Gallo JM.

Mt Sinai J Med. 2010 Jul-Aug;77(4):381-8. doi: 10.1002/msj.20193. Review.

Supplemental Content

Loading ...
Support Center